-
【ASH Express】Reproduce eye-catching data-a quick overview of the blockbuster study of the classic BTK inhibitor ibrutinib
Time of Update: 2023-01-06
The 2022 American Society of Hematology (ASH) Annual Meeting will be held in New Orleans from December 10 to 13 Eastern Time in the form of online + offline, the abstract will be announced at 22:00 Be
-
【ASH Express】Reproduce eye-catching data-a quick overview of the blockbuster study of the classic BTK inhibitor ibrutinib
Time of Update: 2023-01-06
The 2022 American Society of Hematology (ASH) Annual Meeting will be held in New Orleans from December 10 to 13 Eastern Time in the form of online + offline, the abstract will be announced at 22:00 Be
-
Johnson & Johnson 2022Q3: blockbuster products face patent cliff, ibrutinib is "besieged"
Time of Update: 2022-10-31
Sales of ustekinumab, a blockbuster product in the field of self-exemption, exceeded $2 billion, but the patent cliff is coming In the third quarter, Johnson & Johnson's self-immunity revenue was $4.
-
BRUKINSA? (zebrutinib) vs. Eco? A Phase 3 clinical trial (ibrutinib) for chronic lymphocytic
Time of Update: 2022-10-20
62em; font-family:"Arial"; color:black; margin:0in; } BEIJING, China, Cambridge, Massachusetts and Basel, Switzerland, Oct. 12, 2022 /PRNewswire/ -- BeiGene (NASDAQ: BGNE; HKEx code: 06160; SSE: 688235) is a global biotechnology company focused on developing innovative, affordable anti-tumor drugs for patients around the world, improving patient outcomes and increasing drug access.
-
Simcere Pharmaceutical's "ibrutinib" first generic approved for marketing! Original Research Institute's sales in 2021 were USD 9.8 billion
Time of Update: 2022-10-20
Ibrutinib is the world's first marketed BTK inhibitor, and the original product Imbruvica was developed by Johnson & Johnson and Pharmacyclics.
Ibrutinib is the world's first marketed BTK inhibitor, and the original product Imbruvica was developed by Johnson & Johnson and Pharmacyclics.
-
SOHO 2022: Zebrutinib has better ORR and PFS benefits than ibrutinib in patients with relapsed/refractory CLL/SLL disease
Time of Update: 2022-10-19
1% of patients in the zebrutinib and ibrutinib groups, respectively, had received more than three prior lines of treatment.
1% of patients in the zebrutinib and ibrutinib groups, respectively, had received more than three prior lines of treatment.
-
FDA approves ibrutinib for children with chronic GVHD
Time of Update: 2022-09-24
ly/3cgRdJ8 Based on the results of the Phase 1/2 iMAGINE trial, the FDA has approved ibrutinib for patients with chronic graft-versus-host disease in children .
ly/3cgRdJ8 Based on the results of the Phase 1/2 iMAGINE trial, the FDA has approved ibrutinib for patients with chronic graft-versus-host disease in children .
-
BeiGene's final response assessment for zanubrutinib achieves primary endpoint superiority over ibrutinib
Time of Update: 2022-05-23
On April 11, BeiGene announced the final response assessment results of the ALPINE study of the global Phase 3 clinical trial of zanubrutinib (Baiyueze®): the independent review committee (IRC) confirmed that in patients with relapsed or refractory (R /R) In adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), the BTK inhibitor Baiyueze® (zanubrutinib) demonstrated superior overall response rate (ORR) to ibrutinib ) .
-
Fixed-duration therapy with ibrutinib combined with veneclax has excellent efficacy in newly diagnosed CLL patients
Time of Update: 2022-04-29
Here, the investigators report the results of the primary analysis of the CAPTIVATE FD cohort of fixed-duration first-line treatment of CLL/SLL with ibrutinib plus veneclax .
-
Induction therapy with ibrutinib and rituximab is safe and effective in young patients with newly diagnosed MCL: the WINDOW-1 study
Time of Update: 2022-04-28
Table 1: Baseline Characteristics of Patients in the WINDOW-1 Study Patient Short-Term Response Patients received a median of 7 cycles of treatment in Part A and 4 cycles in Part B.
-
Blood: Obinutuzumab + ibrutinib + venetoclax for first-line treatment of high-risk chronic lymphocytic leukemia
Time of Update: 2022-04-21
Finally, patients who did not achieve complete remission (CR) after consolidation therapy and had several consecutive undetectable minimal residual disease (uMRD) received an additional 24 cycles of ibrutinib monotherapy .
-
J Clin Oncol: Ibrutinib (ibrutinib) combined with Rituximab (rituximab) in the treatment of indolent mantle cell lymphoma (IMCL-2015)
Time of Update: 2022-01-23
Recently, the Journal of Clinical Oncology published the results of a phase II study IMCL-2015 from Spain , which mainly evaluated the use of Ibrutinib (ibrutinib) in combination with Rituximab in patients with clinically indolent mantle cell lymphoma (MCL).
-
J. Clin. Med: Long-term efficacy and safety of ibrutinib in patients with CLL: a real-life experience.
Time of Update: 2022-01-22
In addition to the information collected in clinical trials, there is little data on the real-life use of ibrutinib, and only a few studies have mature data on its long-term outcomes, survival, and adherence to treatment .
-
Acatinib brings hope to patients with ibrutinib intolerance to R/R CLL
Time of Update: 2021-12-06
Based on this, some researchers have explored the efficacy and safety of acatinib in patients with R/R CLL who are intolerant to the treatment of ibrutinib and whose disease continues to be active .
-
J Clin Oncol: The efficacy of ibrutinib combined with rituximab in the first-line treatment of elderly patients with mantle cell lymphoma
Time of Update: 2021-12-03
LymphomaThis is a single-center, single-arm phase 2 clinical trial to study the effectiveness and effectiveness of ibrutinib and rituximab (IR) in the treatment of previously untreated elderly MCL patients (≥65 years of age) Security .
